Shares of Novartis fell more than 3% on Monday after its cholesterol drug failed in a closely watched study, dealing ‌a blow ...

New 2026 ESC guidelines explain how cardiovascular and kidney disease influence each other and recommend wider kidney ...

Novo Nordisk A/S stopped two more trials for its experimental heart disease medicine, in a further blow to the drug’s ...

Earlier this year, Novo said ziltivekimab failed to reduce the risk of heart attacks and strokes, diminishing expectations ...

AIIMS probes a 15-year-old’s death after years of congenital heart disease care, highlighting the challenges of treating ...

Ham, bacon and salami raise the biggest health concerns among red meats. Here's what experts say about the risks and which ...

A Chinese medical team achieved a world first by successfully using an AI-driven, ultrasound-guided ...

Nearly 1 in 3 adults is sleep-deprived, and now it counts as a core heart-health risk.

From aortic stenosis to the five variants of a common liver disease, Mayo Clinic scientists recently published research papers in three major journals.

Novartis faces second trial setback as heart drug pelacarsen fails to reduce heart attacks or strokes, shares drop.

Researchers found that urolithin A improved relaxation in engineered human heart tissue and reduced several hallmarks of ...

PARIS — More than 2.7 billion people including children have been exposed to second-hand smoke globally, contributing to ...